1-Oxa-2-aza-spiro[4.5]dec-2-ene-3,8-dicarboxylic acid 3-ethyl ester | 679003-81-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 1-Oxa-2-aza-spiro[4.5]dec-2-ene-3,8-dicarboxylic acid 3-ethyl ester
• 英文别名: 3-Ethoxycarbonyl-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid
• CAS: 679003-81-7
• 化学式: C₁₂H₁₇NO₅
• 分子量: 255.271
• InChiKey: KPZCRBUDRFEPRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  85.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1-Oxa-2-aza-spiro[4.5]dec-2-ene-3,8-dicarboxylic acid 3-ethyl ester 在 N-甲基吗啉 、 lithium hydroxide 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-3-{[8-(1H-Imidazol-2-ylcarbamoyl)-1-oxa-2-aza-spiro[4.5]dec-2-ene-3-carbonyl]-amino}-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid; compound with trifluoro-acetic acid
  参考文献：
  名称：

  Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds

  摘要：

  Analogues of isoxazoline alpha(v)beta(3) antagonist 1 designed to further restrict the four carbon alkyl tether were prepared by incorporating two spirocyclic scaffolds, 1-oxa-2-azaspiro[4,5]dec-2-ene and 1-oxa-2,7-diazaspiro[4,4]non-2-ene. Additional optimization provided potent antagonists of both alpha(v)beta(3) and alpha(5)beta(1) which are selective over GPIIb/IIIa. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.10.057
• 作为产物：
  描述：

  8-Hydroxymethyl-1-oxa-2-aza-spiro[4.5]dec-2-ene-3-carboxylic acid ethyl ester 在 jones reagent 作用下， 生成 1-Oxa-2-aza-spiro[4.5]dec-2-ene-3,8-dicarboxylic acid 3-ethyl ester
  参考文献：
  名称：

  Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds

  摘要：

  Analogues of isoxazoline alpha(v)beta(3) antagonist 1 designed to further restrict the four carbon alkyl tether were prepared by incorporating two spirocyclic scaffolds, 1-oxa-2-azaspiro[4,5]dec-2-ene and 1-oxa-2,7-diazaspiro[4,4]non-2-ene. Additional optimization provided potent antagonists of both alpha(v)beta(3) and alpha(5)beta(1) which are selective over GPIIb/IIIa. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.10.057